ArticleBMC women's health2026
Utility of SOX2 in the diagnosis of squamous intraepithelial lesions and squamous cell carcinoma of cervix uteri.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to examine the association between SOX2 expression and diagnostic and prognostic data in precancerous and cancerous lesions of the cervix uteri. It was postulated that SOX2 immunohistochemistry has the potential to serve as a diagnostic marker for classifying squamous intraepithelial lesions and as a predictor of invasion.
methodsThe immunohistochemical staining of SOX2 was investigated in 210 cervical biopsies obtained from the archives of the Pathology Department of Gaziantep University Faculty of Medicine between January 2017 and June 2022. The samples were grouped according to their diagnosis, namely benign (normal/squamous metaplasia) (n = 28), cervical intraepithelial neoplasia 1 (CIN1) (n = 50), cervical intraepithelial neoplasia 2 (CIN2) (n = 50), cervical intraepithelial neoplasia (CIN3) (n = 50) and squamous cell carcinoma (SCC) (n = 32). The correlation between the expression status and prognostic parameters was analyzed.
resultsThe expression of SOX2 was observed in 62.5% of SCC cases, 70% of CIN3 cases and 26% of CIN2 cases. A statistically significant difference in expression was observed between the CIN1 and CIN2/3 groups and the noninvasive-invasive group. No significant correlation was identified between SOX2 expression and prognostic parameters in SCC group.
conclusionsA notable increase in SOX2 expression was evident as the lesions progressed from normal squamous epithelial cells to those exhibiting CIN1, CIN2, CIN3, and finally, SCC. The results of this study suggest that SOX2 may be utilized as a diagnostic tool to facilitate the differentiation between low grade squamous intraepithelial lesion (LSIL or CIN1) and high grade squamous intraepithelial lesion (HSIL or CIN2/CIN3). Moreover, it has the potential to assist in the differentiation of CIN2 from CIN3 and SCC in cases where the invasion is debatable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.